GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotron Ltd (OTCPK:BITRF) » Definitions » Debt-to-Revenue

Biotron (Biotron) Debt-to-Revenue : N/A (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Biotron Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Biotron's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.02 Mil. Biotron's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Biotron's annualized Revenue for the quarter that ended in Dec. 2023 was $0.00 Mil.


Biotron Debt-to-Revenue Historical Data

The historical data trend for Biotron's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotron Debt-to-Revenue Chart

Biotron Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Biotron Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A 21.50 N/A N/A

Competitive Comparison of Biotron's Debt-to-Revenue

For the Biotechnology subindustry, Biotron's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotron's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotron's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biotron's Debt-to-Revenue falls into.



Biotron Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Biotron's Debt-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.026 + 0.005) / N/A
=N/A

Biotron's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.


Biotron Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biotron's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotron (Biotron) Business Description

Traded in Other Exchanges
Address
56 Delhi Road, Suite 3.3, North Ryde, Sydney, NSW, AUS, 2113
Biotron Ltd is a biotechnology company. It is engaged in the funding and management of intermediate and applied biotechnology research and development projects. Its antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia through biotechnology segment.

Biotron (Biotron) Headlines

From GuruFocus

Biotron Drug Effective Against COVID-19 In Animals

By PRNewswire PRNewswire 11-25-2021